» Articles » PMID: 28039180

Multimodality Treatment for Esophageal Adenocarcinoma: Multi-center Propensity-score Matched Study

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2017 Jan 1
PMID 28039180
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The primary aim of this study was to compare survival from neoadjuvant chemoradiotherapy plus surgery (NCRS) versus neoadjuvant chemotherapy plus surgery (NCS) for the treatment of esophageal or junctional adenocarcinoma. The secondary aims were to compare pathological effects, short-term mortality and morbidity, and to evaluate the effect of lymph node harvest upon survival in both treatment groups.

Methods: Data were collected from 10 European centers from 2001 to 2012. Six hundred and eight patients with stage II or III oesophageal or oesophago-gastric junctional adenocarcinoma were included; 301 in the NCRS group and 307 in the NCS group. Propensity score matching and Cox regression analyses were used to compensate for differences in baseline characteristics.

Results: NCRS resulted in significant pathological benefits with more ypT0 (26.7% versus 5%; P < 0.001), more ypN0 (63.3% versus 32.1%; P < 0.001), and reduced R1/2 resection margins (7.7% versus 21.8%; P < 0.001). Analysis of short-term outcomes showed no statistically significant differences in 30-day or 90-day mortality, but increased incidence of anastomotic leak (23.1% versus 6.8%; P < 0.001) in NCRS patients. There were no statistically significant differences between the groups in 3-year overall survival (57.9% versus 53.4%; Hazard Ratio (HR)= 0.89, 95%C.I. 0.67-1.17, P = 0.391) nor disease-free survival (52.9% versus 48.9%; HR = 0.90, 95%C.I. 0.69-1.18, P = 0.443). The pattern of recurrence was also similar (P = 0.660). There was a higher lymph node harvest in the NCS group (27 versus 14; P < 0.001), which was significantly associated with a lower recurrence rate and improved disease free survival within the NCS group.

Conclusion: The survival differences between NCRS and NCS maybe modest, if present at all, for the treatment of locally advanced esophageal or junctional adenocarcinoma. Future large-scale randomized trials must control and monitor indicators of the quality of surgery, as the extent of lymphadenectomy appears to influence prognosis in patients treated with NCS, from this large multi-center European study.

Citing Articles

Lymph node metastases status in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: a single-center cross-sectional study.

Nguyen A, Pham V, Tran M, Nguyen P Transl Gastroenterol Hepatol. 2025; 10:8.

PMID: 39944591 PMC: 11811556. DOI: 10.21037/tgh-24-76.


Cardiopulmonary exercise variables and their association with postoperative morbidity and mortality after major oesophagogastric cancer surgery-a multicentre observational study.

West M, Rahman S, Jack S, Grocott M, Levett D, Rashid Y BJA Open. 2024; 10:100289.

PMID: 38947220 PMC: 11214286. DOI: 10.1016/j.bjao.2024.100289.


Effects of neoadjuvant chemotherapy chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis.

Csontos A, Fazekas A, Szako L, Farkas N, Papp C, Ferenczi S World J Gastroenterol. 2024; 30(11):1621-1635.

PMID: 38617451 PMC: 11008422. DOI: 10.3748/wjg.v30.i11.1621.


Application of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in curative surgery for esophageal cancer: A meta-analysis.

Yuan M, Cai Q, Zhang Z, Zhou J, Lan C, Lin J World J Gastrointest Oncol. 2024; 16(1):214-233.

PMID: 38292844 PMC: 10824113. DOI: 10.4251/wjgo.v16.i1.214.


History and evidence for state of the art of lymphadenectomy in esophageal cancer surgery.

Schuring N, van Berge Henegouwen M, Gisbertz S Dis Esophagus. 2023; 37(4).

PMID: 38048446 PMC: 10987971. DOI: 10.1093/dote/doad065.


References
1.
DAgostino Jr R . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19):2265-81. DOI: 10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b. View

2.
Talsma A, Shapiro J, Looman C, van Hagen P, Steyerberg E, van der Gaast A . Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 2014; 260(5):786-92. DOI: 10.1097/SLA.0000000000000965. View

3.
Chu K, Law S, Fok M, Wong J . A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg. 1997; 174(3):320-4. DOI: 10.1016/s0002-9610(97)00105-0. View

4.
Markar S, Wiggins T, Ni M, Steyerberg E, van Lanschot J, Sasako M . Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review. Lancet Oncol. 2015; 16(1):e23-31. DOI: 10.1016/S1470-2045(14)70419-X. View

5.
Shapiro J, van Klaveren D, Lagarde S, Toxopeus E, van der Gaast A, Hulshof M . Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery. Br J Surg. 2016; 103(8):1039-47. DOI: 10.1002/bjs.10142. View